Dutch biotech Leyden Labs has raised €40m from a group of investors to advance its nasal spray approach for protection against influenza and other respiratory viruses.
Tag Archive for: fundraising
London’s RQ Bio, a private biotech developing long-acting antibody therapeutics to prevent flu, has raised $115 million (£85.5 million/€101 million) in its Series A financing.
Finnish biotech Aplagon has raised €4.8m to broaden Phase II development of its lead candidate APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The financing will support a new Phase II clinical programme in arteriovenous fistula (AVF) maturation failure in patients with end-stage kidney disease.
Oslo-based Circio has completed a NOK300m (€27m) financing round, extending its runway to the end of 2030 and giving the company funds to advance its circVec circular RNA expression platform toward IND-enabling development and clinical proof-of-concept.
Barcelona-based Ona Therapeutics has raised US$86.6m in a Series B financing to advance a new generation of antibody-drug conjugates into clinical development.
Nanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect.
Unsplash+Finnish clinical stage biotech TenBoron Oy has landed a €7.6m grant from the European Union’s Horizon Europe Health 2025 programme. The funding will propel its boron carrier platform for a novel targeted radiotherapy into larger clinical trials for cancers with few remaining treatment options.
UK biotech Mestag Therapeutics has raised $40 million and appointed veteran drug developers Lindsey Rolfe as chief medical officer and Pascal Merchiers as chief development officer, as the company prepares to start its first clinical trial in cancer in mid-2026. The new financing brings total capital committed to the Cambridge-based company to more than $95 million, following its $11 million launch round in April 2021 and a seed extension that took total seed financing to $45 million in August 2021.
Aerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was co-led by EQT Life Sciences through its LSP Dementia Fund, alongside age1, and brings the company’s total funding to €50 million since its seed round in October 2025.
The transatlantic venture firm Epidarex Capital has reached a first close of more than $145 million (approximately €121.6 million) to focus on company creation and early-stage investments across the UK and the US.